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Abstract
Background: It has recently been proposed that the M-type phospholipase A2 receptor (PLA2R1) acts as a tumour
suppressor in certain malignancies including mammary cancer. Considering that DNA methylation is an important
regulator of gene transcription during carcinogenesis, in the current study we analyzed the PLA2R1 expression,
PLA2R1 promoter methylation, and selected micro RNA (miRNA) levels in normal human mammary epithelial cells
(HMEC) and cancer cell lines.
Methods: Levels of PLA2R1 and DNA methyltransferases (DNMT) specific mRNA were determined using real-time
RT-PCR. Methylation specific-high resolution melting (MS-HRM) analysis was utilized to quantify the methylation
degree of selected CpG sites localized in the promoter region of the PLA2R1 gene. Expression of miRNA was tested
using miScript Primer Assay system.
Results: Nearly complete methylation of the analyzed PLA2R1 promoter region along with PLA2R1 gene silencing
was identified in MDA-MB-453 mammary cancer cells. In MCF-7 and BT-474 mammary cancer cell lines, a higher
DNA methylation degree and reduced PLA2R1 expression were found in comparison with those in normal HMEC.
Synergistic effects of demethylating agent (5-aza-2′-deoxycytidine) and histone deacetylase inhibitor (trichostatin A)
on PLA2R1 transcription in MDA-MB-453 cells confirmed the importance of DNA methylation and histone modification
in the regulation of the PLA2R1 gene expression in mammary cells. Furthermore, significant positive correlation between
the expression of DNMT1 and PLA2R1 gene methylation and negative correlation between the cellular levels of
hsa-mir-141, −181b, and -181d-1 and the expression of PLA2R1 were identified in the analyzed cells. Analysis of
combined z-score of miR-23b, −154 and -302d demonstrated a strong and significant positive correlation with
PLA2R1 expression.
Conclusions: Our data indicate that (i) PLA2R1 expression in breast cancer cells is controlled by DNA methylation
and histone modifications, (ii) hypermethylation of the PLA2R1 promoter region is associated with up-regulation of
DNMT1, and (iii) hsa-miR-23b, −154, and −302d, as well as hsa-miR-141, −181b, and −181d-1 are potential candidates
for post-transcriptional regulation of PLA2R1 expression in mammary cancer cells.
Background
M-type phospholipase A2 receptor (PLA2R1) is a 180 kDa
transmembrane glycoprotein that belongs to the C-type lec-
tin superfamily and the mannose receptor family. PLA2R1
consists of cystein-reach domain, fibronectin type II do-
main and eight carbohydrate recognition domains [1, 2].
The receptor binds secreted phospholipases A2 (sPLA2)
with distinct affinities [3, 4]. As result of sPLA2 binding to
PLA2R1, the amount of sPLA2 is lowered in extracellular
milieu and its cellular signaling cascades linked to apoptosis
and senescence are switched on [4]. A soluble form of the
receptor is constitutively present in circulation as an en-
dogenous inhibitor for mammalian sPLA2s [3].
Limited number of studies addressed the pathophysio-
logical role of PLA2R1. It has been shown that PLA2R1
is the major podocyte autoantigen associated with devel-
opment of idiopathic membranous nephropathy [5, 6].
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Anti-PLA2R1 autoantibodies bind to conformational
epitopes on the receptor, form immune complexes
which stimulate the release of cytokines and metallopro-
teinases; that, in turn, result in proteinuria [5–7]. Recent
studies uncovered a novel tumour suppressive function
of PLA2R1. The receptor exerted anti-tumour responses
including cellular senescence, apoptosis and inhibition of
cell transformation [8–11]. For instance, the ability of
human mammary epithelial cells (HMEC) to overcome
oncogenic stress–induced senescence was improved
after downregulation of PLA2R1 levels in vitro [10]. Fur-
thermore, in mammary cancer cell lines MDA-MB-231
and Cama-1 the constitutive expression of PLA2R1 was
found to block the colony growth in soft agar, support-
ing a tumour suppressive role of PLA2R1 [10]. Contrary,
knockdown of PLA2R1 increased the transformed pheno-
type of MDA-MB-436 breast cancer cells as measured by
the increased size of soft agar colonies. In addition,
PLA2R1-deficient mice displayed increased sensitivity to
RAS-induced tumourigenesis by facilitating oncogenic
stress-induced senescence escape in vivo, highlighting the
role of the receptor as tumour suppressor [10].
PLA2R1 expression was found decreased in leukaemia,
mammary, renal and thyroid cancers [9, 12–15]. While
the receptor is down-regulated in these cancers, signifi-
cant up-regulation of PLA2R1 was described in the
prostate cancer cell lines PC-3 and DU-145 in compari-
son to normal prostate cells [16]. High expression of
PLA2R1 was also identified in ovarian carcinoma effu-
sions, human leukemic blasts and dermatofibrosarcoma
[17–19]. However, detailed functions and mechanisms of
PLA2R1-mediated signalling in normal and different
cancer cells remain to be elucidated.
It is well-known that epigenetic mechanisms play a
crucial role in cell reprogramming during carcinogen-
esis. DNA methylation, histone modification, and post-
transcriptional gene regulations by non-coding RNAs
(microRNAs, long non-coding RNAs, and small nuclear
RNAs) were also detected at earlier stages of neoplastic
transformation essential for cancer initiation and pro-
gression [20]. We have recently detected PLA2R1 pro-
moter hypermethylation in leukemic cell lines and
leukocytes of patients with leukemia [12]. More hyper-
methylations of CpG sites in the PLA2R1 promoter region
were recently found in PLA2R1-negative kidney cell lines
compared to PLA2R1-positive cells [14]. To decrease the
tumour suppressive effect, cancer cells may exploit hyper-
methylation of the PLA2R1 promoter as gene silencing
mechanism [12].
The purpose of this study was to examine expression
of PLA2R1, degree of PLA2R1 promoter methylation,
and expression of methylation regulating enzymes DNA-
methyltransferases (DNMT) in normal and mammary
cancers cell lines. Levels of distinct miRNAs that may
target PLA2R1 mRNA were also assessed. Correlations
among expression of PLA2R1, degree of PLA2R1 gene
methylation and related miRNAs were tested.
Methods
Cell culture and treatments
Human mammary epithelial cells (HMEC) were from
Lonza (Köln, Germany) and the human UACC-812 and
MCF-7 mammary cancer cell lines were from the
American Type Culture Collection (Rockville, MD, USA).
Additional human mammary cancer cell lines, Cal-51, BT-
474 and MDA-MB-453, were obtained from the German
Collection of Microorganisms and Cell Cultures (Berlin,
Germany). HMEC were cultured in MEGM culture
medium and MCF-7 cells in RPMI 1640 culture medium
supplemented with 10 % FCS at 37 °C in a humidified at-
mosphere of 5 % CO2. Cal-51, BT-474 and MDA-MB-453
cell lines were cultured in L-15 (Leibovitz) medium
(Sigma-Aldrich) supplemented with 20 % FCS and incu-
bated at 37 °C under conditions of free gas exchange with
atmospheric air. All cells were incubated in the pres-
ence of 1 % penicillin/streptomycin (Invitrogen) and
0.36 % gentamycin (Invitrogen). Clinicopathological and
biological characteristics of the analyzed cell lines were
described in details elsewhere [21–23].
To estimate the role of epigenetic mechanisms in
PLA2R1 expression, 5-aza-2′-deoxycytidine and trichos-
tatin A (TSA, Sigma-Aldrich; Deisenhofen, Germany)
were used as described previously [24]. MDA-MB-453
cells were seeded at a density of 5 × 105 cells per well
into 24-well tissue culture plates 24 h before 5-aza-dC
and TSA treatments. Cells were treated with 1 μM 5-
aza-dC for 72 h and 0.3 μM TSA for 24 h alone and in
combination. During combined treatment, cells were
exposed first to 1 μM 5-aza-dC for 48 h and then to
0.3 μM TSA for the following 24 h together with 5-aza-
dC. After incubation, cells were harvested and DNA and
RNA were isolated for MS-HRM and real-time RT-PCR
analyses.
Extraction of genomic DNA and RNA
Genomic DNA and RNA were isolated from normal
HMEC and mammary cancer cell lines using the Blood &
Cell Culture DNA Mini Kit from Qiagen GmbH (Hilden,
Germany) and TRI Reagent from Sigma-Aldrich accord-
ing to the manufacturer’s instructions.
Analysis of miRNA expression
Micro RNAs (miRNA) were isolated from normal and
cancer cells using the miRNeasy Mini and RNeasy
MinElute Cleanup Kits (Qiagen GmbH) according to
manufacturer’s instructions. The expression of miRNAs
was analyzed using the miScript Primer Assay system
(Qiagen GmbH) with the Rotor-Gene Q (Qiagen
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GmbH). Data were analyzed using the comparative
quantification method wherein relative levels of miRNA
were normalized to non-coding small nuclear RNA U6
(U6 snRNA) level. The following miScript Primer Assays
were used: MS00031633 (Hs_miR-23a_2), MS00031647
(Hs_miR-23b_2), MS00022897 (Hs_miR-23c_1), MS00
003507 (Hs_miR-141_1), MS00003570 (Hs_miR-149_1),
MS00003598 (Hs_miR-154_1), MS00006699 (Hs_miR-
181b_1), MS00045969 (Hs_miR-181d-3p_1), MS00031
500 (Hs_miR-181d_2), MS00003920 (Hs_miR-302d_1),
MS00009835 (Hs_miR-501-5p_1) and MS00033740 for
U6 snRNA (Hs_RNU6-2_11).
Quantitative RT-PCR analyses
Isolated RNA was converted to cDNA using the
GeneAmp RNA-PCR Kit (PerkinElmer LAS GmbH,
Jügesheim, Germany). For quantitative RT-PCR, portions
of the reverse transcribed reaction products were ampli-
fied for identification of PLA2R1 expression comparing
to GAPDH levels used as reference gene. Real-time RT-
PCR was performed using Rotor-Gene Q and Rotor
Gene SYBR Green PCR kit (Qiagen GmbH) according
to manufacturer’s instructions. The primer pairs used for
the analyses of GAPDH and PLA2R1 expression were:
GAPDH, forward 5′-CGG AGT CAA CGG ATT TGG
TCG TAT TG-3′ and reverse 5′-GCA GGA GGC ATT
GCT GAT GAT CTT G-3′ giving PCR products with a
length of 439 bp [25]; PLA2R1, forward 5′-CAG AAG
AAA GGC AGT TCT GGA TTG-3′ and reverse 5′-
AAA GCC ACA TCT CTG GCT CTG ATT-3′ for
PLA2R1, giving PCR products with a length of 325 bp.
DNA methyltransferases primer sequences were: DNMT1,
forward 5′-GTG GGG GAC TGT GTC TCT GT-3′ and
reverse 5′-TGA AAG CTG CAT GTC CTC AC-3′ giving
PCR product with a length of 204 bp; DNMT3A, forward
5′-CCA GTT AGC AGC AGG GAG AC-3′ and reverse
5′-CAA GAG GTA ACA GCG GCT TC-3′ giving PCR
product with a length of 119 bp and DNMT3B, forward
5′-CAG GGA AAA CTG CAA AGC TC-3′ and reverse
5′-ATT TGT TAC GTC GTG GCT CC-3′ giving PCR
product with a length of 296 bp. Primers were applied in a
final concentration of 0.8 μM. The conditions for amplifi-
cation were as follows: 40 courses at 95 °C for 5 s and 58 °
C for 10 s. At the beginning of real-time RT-PCR analyses,
the size and purity of the amplification products were
confirmed using agarose gel electrophoresis.
Methylation-specific high resolution melting (MS-HRM)
analyses
MS-HRM analyses were conducted to quantify the de-
gree of methylation in the distinct region from −437 bp
to −270 bp of exon 1 of the PLA2R1 gene
(ENSG00000153246, transcript: PLA2R1-001 ENST0000
0283243). The analyses were performed using Rotor-
Gene Q and the EpiTect MS-HRM PCR kit (Qiagen
GmbH) according to manufacturer’s instructions. The ap-
plied primer pairs for PLA2R1, standards and additional
details of the MS-HRM analyses were described previ-
ously [12, 26]. Briefly, bisulfite modified unmethylated and
methylated standard DNA (Qiagen GmbH) were mixed
giving samples with 0, 10, 25, 50, 75, and 100 % methyla-
tion degrees for calibration. A standard curve with known
methylation degrees was included in each run. The ap-
plied primer pairs for PLA2R1 were 5′-GGG GTA AGG
AAG GTG GAG AT-3′ and 5′-ACA AAC CAC CTA
AAT TCT AAT AAA CAC-3′ giving PCR products with a
length of 168 bp. The primers were applied at a final con-
centration of 0.8 μM. The conditions of amplification were
as follows: 40 courses at 95 °C for 10 s, 58 °C for 30 s and
72 °C for 15 s. Immediately after PCR, the products were
analyzed by high resolution melting analysis with fluores-
cence measured during the linear temperature transition
from 50 to 95 °C at 0.01 °C/s.
In silico analyses
MethPrimer software [27] was used to establish primers
for MS-HRM and assess the presence of 5′-CpG islands
in the promoter region of the PLA2R1 gene. Prediction
of putative binding sites for transcription factors in the
PLA2R1 promoter region was performed using Promo
software V.3 [28]. Search of candidate miRNAs which
might target the PLA2R1 gene expression was performed
using following prediction programs: miRDB (http://
mirdb.org/cgi-bin/search.cgi), microRNA.org-Targets and
Expression (http://www.microrna.org). Data were also
assessed using MirWalk program, which includes infor-
mation about miRNA target interactions produced by
established miRNA prediction programs on 3′ UTRs of
all known human, mouse and rat genes [RNA22, mi-




The differences between the studied groups were ana-
lyzed with Kruskal-Wallis one way test of variance on
ranks. The correlations between variable pairs were
studied using Pearson product moment correlation test.
All statistical analyses were performed using the statis-
tics module integrated in the SigmaPlot 11.2 software
(Systat Software GmbH, Erkrath, Germany). Differences
were considered significant at p < 0.05.
Results
Using MS-HRM and in silico analyses we identified po-
tential transcription factor binding sites in the PLA2R1
promoter region. We suggested that the region from
−270 bp to −437 bp might contain CpG sites for E2F-1
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and NFI/CTF or those located near CpG sites for C/
EBP-β, p53, c-Jun/c-Fos, and LEF/CTF (Fig. 1a). MS-
HRM analyses demonstrated differential PLA2R1 pro-
moter methylations in HMEC and breast cancer cell
lines (Fig. 1b and c). In normal cells and CAL-51 and
UACC-812 cancer cell lines the PLA2R1 methylation de-
gree was negligible (<10 %), whereas in MDA-MB-453
cells it reached a value of about 80 %. Simultaneously,
MDA-MB-453 cells demonstrated strongly downregulated
levels of the receptor mRNA representing only ~1 % of
those in HMEC (Fig. 1d). In BT-474 and MCF-7 cells
levels of PLA2R1-specific mRNA were also markedly
reduced, whereas in CAL-51 and UACC-812 cells, levels
of PLA2R1-specific mRNA were similar to those in nor-
mal HMEC (Fig. 1d). The Pearson product moment cor-
relation coefficient between PLA2R1 expression and
PLA2R1 promoter methylation reached −0.664 but the re-
lationship was not statistically significant (Table 1).
To examine the role of DNA methylation and histone
modifications in silencing the PLA2R1 gene expression
MDA-MB-453 cells were exposed to demethylating
agent, 5-aza-dC and histone deacetylase inhibitor, TSA.
MS-HRM analyses revealed a nearly 50 % reduction of
PLA2R1 gene methylation degree with 1.0 μM 5-aza-dC
for 72 h, whereas 0.3 μM TSA for 24 h as expected had
a negligible effect on PLA2R1 promoter methylation in
comparison to untreated control cells (Fig. 2a). Treat-
ment of cells with 5-aza-dC or TSA alone was accom-
panied by 6.7- and 3.3-fold increased PLA2R1 transcript
levels, respectively (Fig. 2b). The combined application
of both agents resulted in a synergistic 20.9-fold re-
expression of PLA2R1 relative to untreated control cells,
suggesting that, in addition to DNA methylation, histone
deacetylation plays an important role in the regulation
of PLA2R1 expression in MDA-MB-453 cells (Fig. 2b).
Next, we analyzed expression levels of DNMT1, the pri-
mary enzyme responsible for copying methylation patterns
after DNA replication [29]. The analysis revealed signifi-
cantly increased levels of DNMT1 transcripts in MDA-
MB-453 cells with the highest PLA2R1 gene methylation
followed by the BT-474 and MCF-7 cell lines (Fig. 3a). The
PLA2R1 methylation degree in mammary cells strongly
correlated with DNMT1 expression level (r = 0.970; p =
0.001, Fig. 3b). In contrast, levels of DNMT3A- and
DNMT3B-specific mRNA were not significantly associated
with PLA2R1 gene methylation (Fig. 3c and d).
Fig. 1 PLA2R1 expression and PLA2R1 promoter methylation in HMEC and mammary cancer cell lines. a Part of the proximal promoter region of
human PLA2R1 gene (ENSG00000153246, transcript is shown. PLA2R1-001 ENST00000283243) expands from −437 to −270 bp relative to exon-1.
The sequence in which the methylation degree was quantified using MS-HRM analysis contains nine CpG sites. Positions of potential transcription
factor binding sites in the proximal part of the PLA2R1 gene are indicated. b Difference plots normalized to the 0 %-methylated standard DNA
sample and a standard curve with 0, 10, 25, 50, 75, and 100 % methylation ratios in black dotted lines (from the bottom up) are shown. Cell lines
(1–6): HMEC, CAL-51, UACC-812, BT-474, MCF-7 and MDA-MB-453, respectively. c Bar graphs show the mean PLA2R1 methylation degree ± SD (%)
calculated from two MS-HRM analyses in triplicates. d Relative expression levels of PLA2R1 and GAPDH as reference gene were determined in
HMEC and mammary cancer cells using real-time RT-PCR. The estimated values of comparative quantification were normalized to levels of expression
in HMEC that was set at 1.0. Results are shown as means ± SD. Analyses were performed in duplicates and experiments were repeated three times. * -
p < 0.05 relative to HMEC values
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Using miRNA prediction software, we identified a
number of PLA2R1 targeting miRNAs (hsa-miR-23a,
−23b, −23c, −141, −149, −154, −181b, −181d-1, −181d-2,
−302d, −501) (Table 2). Figure 4 shows how mean values
of miRNAs expression varied in cancer cells and HMEC.
According to these results miRNAs were differentially
expressed in mammary cells with high (HMEC, CAL-51,
and UACC-812 cells) and low (BT-474, MCF-7, and
MDA-MB-453 cells) levels of PLA2R1 transcripts. Nega-
tive values of Pearson correlation coefficient, −0.628,
−0.495, −0.468, −0.131, and −0.089 were observed for hsa-
miR-141, −181d-1, −181b, −501, and −149, respectively
(Table 2). In contrast, hsa-miR-302d, −154 and −23b
levels positively correlated with receptor mRNA levels. To
select miRNA candidates as possible additional regulators
of PLA2R1 expression, we converted individual miRNA
expression values into z-score that is considered as a use-
ful tool to combine scores from data with different means,
ranges, and standard deviations. Mean of z-values (mean
z-score) allows the assessment of the multiple markers as
a continuous variable [30]. In case of mean z-score of all
miRNAs analyzed in this study, a weak negative Pearson
correlation of this combined score with PLA2R1 expres-
sion was detected (r = −0.077, Table 1). Mean z-scores of
five (hsa-mir-141, −149, −181b, −181d-1, −501) and three
candidate miRNAs (hsa-mir-141, −181b, and −181d-1),
which all were negatively associated with PLA2R1 mRNA
levels, showed a stronger correlation with the receptor ex-
pression (r = −0.581 and −0.721, respectively; Table 1). In
case of mean z-score of hsa-miR-23b, −154, and −302d, a
strong and significant positive correlation with PLA2R1
expression was found (r = 0.923, p = 0.009; Table 1).
Discussion
The findings of this study demonstrate that the PLA2R1
is differentially expressed amongst mammary normal
and cancer cells, and confirm the importance of epigen-
etic mechanisms such DNA methylation and histone
modification in the regulation of PLA2R1 transcript
levels. Similar to previous data obtained in leukemia
cells [12], the analyzed PLA2R1 promoter region was
nearly completely methylated in the mammary cancer
Table 1 Pearson product moment correlation coefficients (r) and
significance (p) between PLA2R1 expression and variables such
PLA2R1 promoter methylation and means of z-score transformed
data of candidate miRNAs expression in HMEC and mammary
cancer cell lines (CAL-51, UACC-812, BT-474, MCF-7, and MDA-MB-
453) are shown. Correlations were analysed using statistical
package of SigmaPlot 11.2 software
Variables Correlation with PLA2R1 expression
r p
PLA2R1 promoter methylation −0.664 0.150
Mean z-score of all miRNAs −0.077 0.885
Mean z-score of hsa-mir-141,
−149, −181b, −181d-1, −501
−0.581 0.227
Mean z-score of hsa-mir-141,
−181b, −181d-1
−0.726 0.102
Mean z-score of hsa-mir-23b,
−154, −302d
0.923 0.009
Fig. 2 Effects of 5-aza-2′-deoxycytidine (5-aza-dC) and trichostatin A (TSA) treatments on PLA2R1 promoter methylation (a) and PLA2R1 expression
(b) in MDA-MB-453 cancer cells. a MS-HRM analysis of PLA2R1 methylations in control cells without treatment (one, green) and after exposure of
MDA-MB-453 cells to 1 μM 5-aza-dC for 72 h (two, red), 0.3 μM TSA for 24 h (three, orange), and in cells treated with both agents (four, blue) as
described in Materials and Methods section. Difference plots were normalized to standard 0 %-methylated DNA sample data. The black dotted
lines represent standard xcurves of 0, 10, 25, 50, 75 and 100 % methylation degrees. Analyses were performed in duplicates and results are
representative of two independent experiments. b Relative expression of PLA2R1-specific mRNA was determined using real-time RT-PCR
and GAPDH-mRNA levels were used as reference in MDA-MB-453 cells. The experimental conditions were the same as described in (a). Values
of comparative quantification were normalized to expression levels of untreated controls that were set at 1.0. Results are shown as means ± SD.
Analyses were performed in triplicates and results are representative of two independent experiments
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cell line MDA-MB-453 where PLA2R1 gene was silenced
(Figs. 1 and 2). These findings are consistent with previ-
ous studies underscoring the role of DNA methylation
in gene silencing mechanism critically involved in cell
cycle regulation, carcinogen detoxification, cell adhesion
and metastasis [31]. In addition to DNA methylation,
the importance of histone modification in PLA2R1 regu-
lation was indicated by the synergistic re-expression of
PLA2R1 after simultaneous treatment of MDA-MB-453
cells with DNA methylation and histone deacetylase in-
hibitors (Fig. 2).
Recently, PLA2R1 was identified as potential tumour
suppressor that controls replicative- and stress-induced
senescence [9, 13, 14]. Normal cells employ cellular sen-
escence to control or prevent carcinogenesis, while
cancer cells suppress senescence to increase their sur-
vival capacity [9, 14, 32]. The importance of PLA2R1 for
regulation of cell life span was confirmed in vivo, as
PLA2R1 knockout mice were more sensitive to RAS-
induced skin tumours [10]. Conversely, constitutive ex-
pression of PLA2R1 in normal cells activated premature
senescence [8, 13]. However, little is known about the
pathophysiological significance of senescence during
mammary carcinogenesis, although recent data indicated
the involvement of senescence in the regulation of mam-
mary cancer progression [32]. Whether the activation of
senescence is linked to levels of PLA2R1 expression in the
investigated subset of cell lines remains unclear. There-
fore, it will be of interest for future studies to assess which






















































































Fig. 3 Expression of DNMT1 (a) and correlation of DNMT transcript levels with PLA2R1 gene methylation degrees (b–d) in HMEC and mammary
cancer cell lines. a Bar graphs show the relative levels of DNMT1-specific mRNA determined using real-time RT-PCR and GAPDH mRNA levels were
used as reference gene. The comparative values were normalized to levels of DNMT1 expression in HMEC that was set at 1.0. Results are shown
as means ± SD. Analyses were performed in duplicates and results are representative of three independent experiments. * - p < 0.05 relative to
HMEC value. b–d Data represent scatter-regression plots of correlation between PLA2R1 promoter methylation and DNMT1 (b), DNMT3A (c) and
DNMT3B (d) expressions in HMEC and mammary cancer cell lines. Values of Pearson product moment correlation coefficient (r) between DNMT
expression and PLA2R1 promoter methylation are shown
Table 2 Expression of different miRNAs in normal HMEC and mammary cancer cell lines. Relative levels of miRNA were normalized
to U6 snRNA level. Pearson product moment correlation coefficients (r) between PLA2R1 and miRNA expressions are shown.
Databases: a - http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/predictedmirnagene.php; b - http://mirdb.org/cgi-bin/
search.cgi; c - http://www.microrna.org/microrna
miRNAs HMEC CAL-51 UACC-812 BT-474 MCF-7 MB-453 r Database
miR-23a 2.610 ± 0.065 1.920 ± 0.160 2.470 ± 0.011 3.020 ± 0.545 3.050 ± 0.080 0.925 ± 0.024 0.085 c
miR-23b 0.692 ± 0.333 1.620 ± 0.045 2.990 ± 0.245 1.080 ± 0.140 2.230 ± 0.055 0.268 ± 0.007 0.277 c
miR-23c 0.0066 ± 0.0625 0.0098 ± 0.0003 0.0148 ± 0.0625 0.0095 ± 0.0625 0.0199 ± 0.0005 0.0018 ± 0.0001 0.022 c
miR-141 1.810 ± 0.140 0.028 ± 0.009 3.780 ± 0.305 2.200 ± 0.120 4.910 ± 0.130 3.100 ± 0.080 −0.628 a, b
miR-149 0.0677 ± 0.012 0.0920 ± 0.0157 0.3040 ± 0.0170 0.0725 ± 0.0045 0.3690 ± 0.0100 0.0404 ± 0.0022 −0.089 a, b, c
miR-154 0.0163 ± 0.0004 0.0012 ± 0.0001 0.0024 ± 0.0002 0.0007 ± 0.0001 0.0008 ± 0.0001 0.0017 ± 0.0001 0.451 a
miR-181b 0.223 ± 0.023 0.820 ± 0.070 0.129 ± 0.004 0.359 ± 0.009 0.483 ± 0.039 1.780 ± 0.032 −0.468 c
miR-181d_1 0.0176 ± 0.0018 0.0007 ± 0.0001 0.0002 ± 0.0001 0.0004 ± 0.0001 0.0005 ± 0.0003 0.1070 ± 0.0086 −0.495 c
miR-181d_2 0.0002 ± 0.0001 0.0271 ± 0.0008 0.0039 ± 0.0013 0.0180 ± 0.0034 0.0162 ± 0.0005 0.0005 ± 0.0002 0.146 c
miR-302d 0.00022 ± 0.00002 0.00637 ± 0.00037 0.00016 ± 0.00009 0.00001 ± 0.00001 0.00007 ± 0.00003 0.00024 ± 0.00004 0.587 a
miR-501 0.0115 ± 0.0013 0.0312 ± 0.0018 0.0554 ± 0.0017 0.0064 ± 0.0006 0.0302 ± 0.0009 0.0570 ± 0.0131 −0.131 a
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which physiological ligands trigger the PLA2R1 mediated
signalling functions in mammary cancers.
The methylation analysis data we observed in MDA-
MB-453, MCF-7 and BT-47 cells (Figs. 1 and 2) are
consistent with previous unsupervised cluster analysis of
methylation-sensitive gene expression [33]. The study re-
vealed a subset of mammary cancer cells, including MDA-
MB-453 cells, which were classified as hypermethylator
cell lines and exhibited aberrant DNA hypermethylations
of distinct genes. This cell line subset exhibited elevated
DNMT activities. In contrast, mammary cancer cells clas-
sified as low-frequency methylator cell lines did not show
increased methylation of specific genes or DNMT activity
[33]. In agreement with these studies we detected an up-
regulation of DNMT1 expression in MDA-MB-453,
MCF-7, and BT-474 cells (Fig. 3) which are characterized
by increased PLA2R1 promoter methylations (Fig. 1).
Whether this DNMT1 expression is causally connected to
the observed PLA2R1 promoter methylation requires fur-
ther investigation.
A growing number of data confirmed that microRNAs
play a crucial role in the regulation of gene expression
via control of post-transcriptional mRNA function. As
“global-regulators” miRNAs direct a diverse range of
cellular responses both in normal and pathological condi-
tions [20, 34]. Expression of miRNA is one of the universal
epigenetic mechanisms implicated in the regulation of
growth and survival pathways in cancer cells [35].
We identified a significant up-regulation of miR-141,
miR-181b, and miR-181d-1 and a down-regulation of
miR-23b, miR-154 and miR-302d in mammary cancer
cells in comparison to HMEC. According to the applied
databases (Table 2), these miRNAs exhibit extended com-
plementarity to the 3′-UTR sequence of PLA2R1 gene.
Therefore, further studies are warranted to confirm regu-
























































































































Fig. 4 Values of miRNAs expression in mammary cancer cell lines normalized to mean values of that in normal HMEC. Bar graphs demonstrate
miRNA levels in cancer cells relative to HMEC that was set at 1.0. Details of miRNA quantification are described in the Materials and Methods
section. Means ± SD values of miRNAs expression are shown in Table 2
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regulators) and hsa-miR-141, −181b, and −181d-1 (nega-
tive regulators) on PLA2R1 expression. The observed
depletion of hsa-miR-154 in all analyzed mammary cancer
cell lines is a novel finding that should also be investigated
in further detail.
Associations between miRNA expression and cancer
progression were reported for different cancer types
[20, 36], while selected miRNAs, that were analysed in this
study, have been described as regulators of carcinogenesis.
For instance, hsa-miR-141 is overexpressed in cisplatin re-
sistant ovarian, gastric and esophageal squamous cancer
cells [37–39]. Furthermore, hsa-miR-141 expression was
associated with chemoresistance in breast cancer patients
receiving neoadjuvant chemotherapy [40] and was ele-
vated in MDA-MB-231 invasive breast carcinoma cell line
[41]. Members of the hsa-miR-181 family were involved in
myeloid differentiation and acute myeloid leukemia [42].
It was noted that hsa-miR-181a/b overexpression coin-
cided with aberrant activation of major signalling path-
ways involved in breast tumourigenesis, including IL6/
STAT3 [43], TGF-β [44, 45], HIF-1 [46], WNT/β-catenin
[47] and HMGA1 [48]. The hsa-miR-181 family has been
shown to be deregulated also in other solid tumours such
pancreas, prostate, gastric and colon cancers and was able
to target tumour suppressors, including TIMP3, CYLD,
PTEN and p27 [43, 45, 49, 50]. Overexpression of hsa-miR-
181a/b in breast cancers correlated with aggressive features
and the likelihood to develop distant metastases [44, 51, 52].
Our findings are consistent with the observation that hsa-
miR-181d-1 and −181b are strongly up-regulated in the
metastatic MDA-MB-453 mammary cancer cell line (Fig. 4).
Among miRNAs, which were positively associated with
PLA2R1 expression in this study, hsa-miR-23b and −154
exerted suppressing effects in different cancers in vitro
and in vivo [53–55]. Consequently, it will be of special
interest to elucidate the effects of distinct miRNA inhibi-
tors on cellular PLA2R1 expression in future studies.
Conclusions
The data of this study indicate that the PLA2R1 is differ-
entially expressed in mammary normal and cancer cells
and that the cellular receptor expression is regulated by
epigenetic mechanisms such as DNA methylation and
histone acetylation. An up-regulation of DNMT1 was
found in cells with high PLA2R1 promoter methylation.
In addition, new candidate miRNAs such as hsa-miR-
23b, −154 and −302d which are positive regulators and
hsa-miR-141, −181b and −181d-1 which are negative
regulators were identified. These miRNAs should be fur-
ther tested as putative regulators of PLA2R1 expression
in mammary cancer cells.
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